Table 2 Alemtuzumab meets almost all the criteria that are expected from the ideal disease-modifying immunosuppressive/immunomodulatory drug for multiple sclerosis
From: Alemtuzumab for multiple sclerosis: the new concept of immunomodulation
| Criteria of the ideal immunosuppressive drug | YES | Partially | NO |
|---|---|---|---|
| Rapid biological action | X | ||
| Rapid clinical effects | X | ||
| Long-lasting effects | X | ||
| Low frequency of injections/administrations | X | ||
| Respect the patient’s quality of life | X | ||
| Acceptable costs | X | ||
| No non-specific toxicity | X | ||
| Low risk of opportunistic infections | X | ||
| No increase risk in cancer | X | ||
| No increase in antibody-mediated autoimmunity | X | ||
| No increase in severe antibody-mediated autoimmunity | X | ||
| No increase in mortality | X | ||
| Manageable cytokine-release syndrome | X | ||
| Immune system re-modelling/re-shaping | X |